US20100137443A1 - Ibuprofen for Topical Administration - Google Patents

Ibuprofen for Topical Administration Download PDF

Info

Publication number
US20100137443A1
US20100137443A1 US12/557,470 US55747009A US2010137443A1 US 20100137443 A1 US20100137443 A1 US 20100137443A1 US 55747009 A US55747009 A US 55747009A US 2010137443 A1 US2010137443 A1 US 2010137443A1
Authority
US
United States
Prior art keywords
solvent
composition
ibuprofen
pyrrolidone
isobutylphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/557,470
Other languages
English (en)
Inventor
Stephen G. Carter
Zhen Zhu
Kanu Patel
Diane L. Kozwich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biochemics Inc
Original Assignee
Biochemics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biochemics Inc filed Critical Biochemics Inc
Priority to US12/557,470 priority Critical patent/US20100137443A1/en
Assigned to BIOCHEMICS, INC. reassignment BIOCHEMICS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KOZWICH, DIANE L., CARTER, STEPHEN G., PATEL, KANU, ZHU, ZHEN
Publication of US20100137443A1 publication Critical patent/US20100137443A1/en
Priority to US13/604,040 priority patent/US9561174B2/en
Assigned to BIO STRATEGIES, LP reassignment BIO STRATEGIES, LP SECURITY INTEREST Assignors: BIOCHEMICS, INC.
Priority to US15/383,381 priority patent/US20170095433A1/en
Priority to US16/576,336 priority patent/US20200009095A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to topical compositions of ibuprofen and methods for making and using the compositions.
  • Ibuprofen an anti-inflammatory, analgesic, and anti-pyretic agent
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Past formulations of ibuprofen have chiefly made use of the water-based form (salt form) of ibuprofen.
  • Ibuprofen in its salt form forms the basis of such drug products as Advil® (potassium salt form of ibuprofen).
  • Use of ibuprofen in its free acid form has been limited to formulations intended for oral administration, e.g., Motrin® in tablet and oral suspension.
  • IBU® Ibuprofen Tablets USP (Knoll Laboratories, Mount Olive, N.J.) is supplied in tablets for oral administration.
  • NSAIDs are highly effective in treating pain and inflammation in joints, muscles and soft tissue, and are generally given orally for a systemic effect.
  • some individuals are unable to tolerate oral intake of ibuprofen.
  • ingestion may result in vomiting, thus leading to ineffective dosing.
  • Others are able to ingest ibuprofen but, as a result, develop gastric mucosal lesions. These lesions lead to gastric discomfort and abdominal pain.
  • the adverse side effects commonly associated with ibuprofen can be avoided by directly administering ibuprofen to an afflicted site in the form of a topical formulation.
  • inventive ibuprofen formulations set forth herein provide an alternate, topical, form of delivery to relieve pain and inflammation, e.g., in muscles, joints and soft tissue, while overcoming many difficulties in formulating a therapeutically effective topical pharmacological composition containing ibuprofen, including low solubility of the free acid form of the drug in aqueous solvents, as well as chemical and physical stability and cosmetic appeal.
  • the ibuprofen composition includes the free acid form of 2-(4-isobutylphenyl)propionic acid, a pharmaceutically acceptable solvent, e.g., a pyrrolidone solvent or dimethylacetamide solvent, and at least one excipient.
  • a pharmaceutically acceptable solvent e.g., a pyrrolidone solvent or dimethylacetamide solvent
  • the 2-(4-isobutylphenyl)propionic acid can have a half-life of at least six months at 25 degrees Celsius.
  • the solvent can be, e.g., a pyrrolidone solvent, e.g., N-methyl-2-pyrrolidone or 2-pyrrolidone, or dimethylacetamide.
  • the 2-(4-isobutylphenyl)propionic acid can be either dissolved or suspended, preferably homogeneously suspended, in a particle or nanoparticle form.
  • the excipient can include one or more of water, a water-soluble excipient, or a water-insoluble excipient.
  • the composition can also include an emulsifier.
  • the 2-(4-isobutylphenyl)propionic acid can be in a protonated form.
  • protonated form means that the ibuprofen is in substantially protonated form, i.e., at least 90% protonated, preferably 95% protonated or even 100% protonated.
  • the excipient can also include a buffer having at least one acid ionization constant, pKa, that is chosen so as to maintain the 2-(4-isobutylphenyl)propionic acid in a substantially protonated form.
  • the buffer can have a pKa of less than 7.
  • the method includes selecting a patient in need of therapy and applying a topical composition to the skin of the patient.
  • the composition includes 2-(4-isobutylphenyl)propionic acid, a pharmaceutically acceptable solvent, e.g., dimethylacetamide, N-methyl-2-pyrrolidone, or 2-pyrrolidone, and at least one excipient.
  • a method of preparing a pharmaceutical composition by solubilizing ibuprofen in a pharmaceutically acceptable solvent, creating an active drug-containing solution by combining the solubilized ibuprofen with a skin conditioner and a preservative, creating an aqueous solution containing a conditioner, a pH stabilizer and a preservative, creating an emollient phase by combining an emulsifier, a preservative, an oil and a stabilizer, combining the emollient phase and the aqueous solution, homogenizing to create a homogenized mixture, and adding the active drug containing solution to the homogenized mixture under temperature conditions avoiding degradation of the ibuprofen.
  • the pyrrolidone solvent can be either N-methyl-2-pyrrolidone or 2-pyrrolidone.
  • At least one of the steps of creating an aqueous mixture, creating an emollient phase, combining and homogenizing can include adding a first amount of heat. A second amount of heat can then be removed prior to the adding the active drug containing solution to create the temperature conditions that avoid degradation of the ibuprofen.
  • FIG. 1 is a flow diagram for a process of formulating a topical ibuprofen composition in accordance with an embodiment of the invention.
  • FIG. 2 is a flow diagram for formulating a topical ibuprofen composition in accordance with another embodiment of the invention in which the composition includes both aqueous and oily ingredients.
  • Topical ibuprofen in the free acid form that is suitable for topical administration.
  • the topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen in solution, or suspending the free acid form of ibuprofen in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of the ibuprofen through the skin tissue.
  • Topical formulations of ibuprofen using a pharmaceutically acceptable solvent e.g., a pyrrolidone solvent or dimethylacetamide.
  • ibuprofen useful in the invention include the acid form, or free acid form, of ibuprofen, known by the chemical names: ( ⁇ )-2-(4-isobutylphenyl)propionic acid; 2-(4-iso-butylphenyl)propionic acid; (4-isobutyl-alpha-methylphenylacetic acid; and 4-iso-butyl-alpha-methylphenylacetic acid and synonyms thereof known to those skilled in the art (hereafter collectively referred to as “2-(4-isobutylphenyl)propionic acid”).
  • ibuprofen suitable for the invention expressly include racemic mixtures of 2-(4-isobutylphenyl)propionic acid and individual stereoisomers thereof. It is understood that “ibuprofen in the acid form” indicates that the ibuprofen molecules in the composition are predominantly or entirely protonated, as distinguished from a salt of the conjugate base or a buffered mixture of acid and base forms.
  • a “nanoparticle” is a particle having one or more dimensions of 1000 nanometers or less.
  • Half life of an active ingredient of a composition means the duration of time elapsing from creation of the formulation until degradation of the formulation reduces by 50% the concentration of the active ingredient in the formulation.
  • “Degradation” of a formulation including an active ingredient includes a process operative over time by which increasing amounts of the active ingredient are inactivated by at least one of chemical reaction and physical separation (such as precipitation).
  • a “formulation” is a preparation in which various chemical substances are combined with an active ingredient, e.g., ibuprofen.
  • a formulation includes a composition of the invention in the form of an ointment, cream, lotion, gel, salve or the like, or a composition by itself, for topical application or delivery of the drug to a patient.
  • a formulation can also include a delivery system (such as a patch) impregnated with or containing a composition including an active ingredient, suitable for topical application.
  • the ibuprofen of the composition can permeate the skin to provide therapeutically effective transdermal delivery of the ibuprofen to a locally affected region.
  • a “pharmaceutically acceptable solvent” is one or more of the solvents listed as being acceptable by the Federal Food and Drug Administration (FDA) in its Inactive Ingredients Database (www.accessdata.fda.gov/scripts/cder/lig/index.cfm; last visited 10 Sep. 2009).
  • a pharmaceutically acceptable solvent must be one which facilitates solubility of the free acid form of ibuprofen, or must be one which facilitates formation of a homogeneous suspension of the free acid form of ibuprofen, to at least 1%, or to at least 5% or 7.5%, preferably to at least 10%, and most preferably to at least 20%, of the formulation on a weight percent basis.
  • ibuprofen compositions are physically and chemically stable and so resist degradation.
  • topical application of the compositions are used to treat inflammatory-related disorders of a patient.
  • pharmaceutically acceptable solvent e.g., a pyrrolidone solvent or a dimethylacetamide solvent, dissolves the free acid form of ibuprofen.
  • a further embodiment of the invention includes a method for manufacturing the composition.
  • ibuprofen is formulated into an ointment composition (e.g. a cream, lotion, gel, salve or like formulation) for topical application.
  • the ibuprofen of the composition can permeate the skin to provide therapeutically effective transdermal delivery of the ibuprofen to a locally affected region (such as an inflamed muscle or joint), to provide anti-inflammatory and/or pain relief.
  • the ibuprofen can permeate to a degree that is sufficient to effect systemic therapy (e.g., to treat a headache or flu).
  • the topical application of therapeutic doses of ibuprofen can result in faster and more effective relief from pain and inflammation than is typically achieved by oral ingestion. When applied topically for local relief, total body dosages should be much lower than with orally ingested ibuprofen, thus reducing side-effects.
  • the table below shows ingredients that can be used in compositions according to embodiments of the invention.
  • the ibuprofen can be enantiomerically pure (e.g., the active S enantiomer) or can be racemic.
  • the ibuprofen can be dissolved or in particulate form. Examples of particulate ibuprofen include micoparticles or nanoparticles with diameters ranging from 10 ⁇ 4 (100 microns) to 10 ⁇ 9 meters (1 nanometer).
  • a particulate acid form of ibuprofen useful for preparing a homogeneous suspension in a pharmaceutically acceptable solvent according to the invention is between 1 and 20 microns in diameter, and more preferably less than 1 micron in diameter.
  • Particles can be produced by microfluidizing and fluid energy milling (see, e.g., U.S. Pat. Nos. 4,851,421; 4,826,689; 4,540,602; 5,145,684 and 6,555,130, each of which is hereby incorporated by reference), a cavitation process, or other suitable methods known to those skilled in the art.
  • Microfluidics-based homogenizers also referred to as “nano-equipment”, are designed to reduce particle sizes by different mechanisms, from multiple microns in diameter to submicron or nanometer sized diameters. These in turn can assist in maximizing the penetration of an agent through the skin and/or into the body by other means of delivery.
  • the ibuprofen is either dissolved or suspended in a pharmaceutically acceptable solvent.
  • the solvent is pharmaceutically acceptable solvent, e.g., a pyrrolidone solvent, for example, a solvent that includes one or more of N-methyl-2-pyrrolidone, and 2-pyrrolidone.
  • the solvent can include dimethylsulfoxide, dimethylformamide, dimethylacetamide, or dimethylisosorbide.
  • the ibuprofen can be dissolved in its free acid form.
  • the formulation can also include at least one excipient, which is a substance serving as a vehicle for the ibuprofen.
  • excipients can be used.
  • the excipients can be present at, e.g., between 1 to 20% wt % of the solvent system.
  • the excipient can include a skin conditioner, an emulsifier, an emulsion stabilizer, a viscosity modifier, a pH buffer, a preservative, an emollient, or a combination thereof.
  • Examples of skin conditioners include L-arginine, menthol, and eucalyptus oil or combinations of these.
  • the skin conditioner can be, for example, 0.1 to 20%, e.g., 0.5% or 1.0%, of the composition by weight.
  • the formulation can contain L-arginine 0.5% as a vasodilator.
  • Nitric oxide (NO) is produced endogenously from arginine in a reaction catalyzed by nitric oxide synthase. NO is one of the primary agents eliciting a vasodilatory response by relaxing vascular smooth muscle, thereby producing an increase in skin blood flow and assisting the ibuprofen to the painful area (e.g., synovial tissue in osteoarthritis).
  • emulsifiers examples include glyceryl stearate, lecithin, and polyoxyl 40 hydrogenated castor oil.
  • the skin emulsifier can be 1 to 40% of the composition by weight.
  • viscosity modifiers examples include xantham gum, Veegum® (R.T. Vanderbilt Co., Inc., Norwalk, Conn.), and PermulenTM (Lubrizol Corporation, Cleveland Ohio).
  • the viscosity modifier can be, for example, 0.1 to 15% of the composition by weight.
  • Ibuprofen has a logarithmic acid dissociation constant, or acid ionization constant (pKa) of about 4.4.
  • An example of a pH buffer i.e., a pH stabilizer
  • citric acid adjusted to an appropriate pK.
  • Citric acid has three ionization constants, with pKa's of 3.15, 4.77, and 6.40 respectively.
  • a buffer of appropriate pH and concentration for a given concentration of ibuprofen citric acid is capable of buffering ibuprofen in a substantially protonated form, e.g., about 90% protonated to about 100% protonated.
  • the buffer concentration can be, for example, 0.1 to 15% of the composition by weight.
  • ibuprofen can be used as a free acid without the use of a buffer.
  • a preservative can be used to prevent spoilage due to microbial growth or oxidation.
  • preservatives include methylparaben and propylparaben, or combinations of these.
  • the preservative is usually included at 0.1 to 5% of the composition by weight, as adjudged by one skilled in the art.
  • An emollient can be included in the composition to soften and soothe the skin, or to correct dryness or scaling of the skin.
  • useful emollients include without limitation lemon oil, olive oil, silicone oil, mineral oil, petrolatum, vegetable wax and mixtures thereof.
  • Emollients can be included at a concentration of, e.g., 1 to 20% of the composition by weight.
  • the excipient can includes water, so as to be at partially aqueous. Care should be taken however that the water concentration is not so high as to cause degradation of the ibuprofen under relevant storage conditions.
  • the excipient can be non-aqueous.
  • the composition can be effective in treatment of conditions including rheumatoid arthritis, osteoarthritis, periarticular disorders and soft tissue injuries, postoperative pain, musculoskeletal pain or the pain or discomfort associated with gout or morning stiffness.
  • the composition can be applied to the affected area and massaged in.
  • the ibuprofen composition can be combined with or impregnated into a patch or other device that is applied to the surface of the skin.
  • a reservoir of solvent e.g., 2-pyrrolidone or N-methyl-2-pyrrolidone
  • the composition can deliver ibuprofen with a time-release or extended-release action (e.g., delivery over 1-8 hours).
  • the ibuprofen is substantially protonated and compatible with the solvent/excipient system, it can have an extended shelf-life (e.g., a half-life of 6 months or more at 25° C.).
  • the flow diagram of FIG. 1 shows a process for manufacturing an ibuprofen composition according to an embodiment of the present invention.
  • ibuprofen is dissolved in a solvent (step 100 ).
  • the solvent can include N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethylsulfoxide, dimethylformamide. dimethylacetamide, dimethylisosorbide or mixtures thereof in amounts sufficient to dissolve the ibuprofen.
  • the ibuprofen amount and concentration can be selected to result in 1-50% ibuprofen in the final formulation.
  • one or more excipients are added (step 110 ). In an embodiment, one or more mixtures of excipients are heated.
  • the excipients can be blended or homogenized. Multiple pools of excipient ingredients can be combined prior to adding the active ibuprofen ingredient.
  • the excipients can be cooled prior to combining with the ibuprofen.
  • the flow diagram of FIG. 2 shows a process for manufacturing an ibuprofen composition according to another embodiment of the present invention.
  • a solvent can include N-methyl-2-pyrrolidone, 2-pyrrolidone, dimethylsulfoxide, dimethylformamide. dimethylacetamide, dimethylisosorbide or mixtures thereof in amounts sufficient to dissolved the ibuprofen.
  • one or more skin conditioners and/or preservatives are added to the ibuprofen-solvent mixture (step 210 ).
  • the water soluble excipient ingredients are combined to form an aqueous solution (step 220 ).
  • the ingredients can be heated (by adding a first amount of heat) and/or mixed (step 230 ), either during or after the combination.
  • a first amount of heat for example, one or more pH buffers, preservatives and skin conditioners can be combined while heating to 70 ⁇ 10° C.
  • the mixing process can include stirring, blending or other homogenization techniques known in the art.
  • hydrophobic (oily) ingredients are combined (step 240 ).
  • the ingredients can be heated and/or mixed (step 250 ), either during or after the combination.
  • the contents of the third vessel can be heated, for example, to 70° C.
  • the mixing process can include stirring, blending or other homogenization techniques known in the art.
  • emulsifiers or other ampiphilic ingredients can be combined with either the aqueous solution in the second vessel or the oily ingredients in the third vessel.
  • the contents of the second vessel (aqueous phase) and third vessel (oil phase) can then be combined (step 260 ) and optionally homogenized.
  • the combined mixture can then be cooled (e.g., heat removal to reach 40° C.) and combined with the contents of the first vessel (dissolved ibuprofen and other optional ingredients. Cooling of the mixture (by removing a second amount of heat) creates conditions that avoid degradation of the ibuprofen. For example, cooling prior to adding the ibuprofen can avoid degradation of the ibuprofen to a substantial degree (e.g., ⁇ 20% degradation).
  • Stability procedure Test formulations are stored in high density polyethylene jars (2 and 4 ounce) with screw caps. The containers are placed at 40° C., 22° C. and 4° C. (degrees Celsius) for periods of time and evaluated for the integrity of the formulation and emulsion stability as well as for quantitative analysis of the ibuprofen content of the batch. The formulation and emulsion integrity are evaluated visually for the presence of phase separation, color, texture or other changes as noted at the time of initial preparation. The quantitative analysis of the ibuprofen is performed with a qualified rugged HPLC method.
  • Ibuprofen formulations prepared according to embodiments described herein are stable, including hydrolytically stable. For example, more than 90% of the therapeutic or biochemical activity of the ibuprofen in the formulation will be active after storage at room temperature ( ⁇ 20-25 degrees Celsius) for at least six months.
  • Example 1 The formulation of Example 1 is prepared as follows. In Tank 1 , dissolve ( ⁇ )-2-(4-isobutylphenyl)propionic acid into N-methyl-2-pyrrolidone until completely solubilized. Add the remaining ingredients of Phase B and mix until completely dissolved. In the Main tank, add the ingredients of Phase C, mix while heating to 70° C. In tank 2 , add the ingredients of Phase A, mix while heating to 70° C. Transfer the contents in Tank 2 into the main tank, mix for 10 minutes, and cool to 40° C. (degrees Celsius) or less. Transfer contents in Tank 1 into Main Tank at 40° C. (degrees Celsius) or less. Mix until blended ( ⁇ 20 minutes).
  • Example 2 The formulation of Example 2 is prepared as follows. In Tank 1 , dissolve menthol into eucalyptus oil until completely solubilized; add remaining ingredients of Phase B and pass through nano-equipment to reduce the particle size. In the main tank, add the ingredients of Phase C, mix while heating to 70° C. In tank 2 , add the ingredients of Phase A, mix while heating to 70° C. Transfer the contents from Tank 2 into Main Tank, mix for 10 minutes; cool to 40° C. (degrees Celsius) or less. Transfer the contents of Tank 1 into the Main Tank at 40° C. (degrees Celsius) or less. Mix until blended ( ⁇ 20 minutes).
  • One hundred grams (100 g) of a 2.5% Carbopol® 980NF solution is prepared as follows. While heating 97.5 g water to 70° C., add 2.5 g Carbopol® 980NF powder with strong mixing (i.e.,. such that a vortex should turn). Mixing is continued until the solution is hydrated and free of clumps at 70° C. The solution is removed from heat and left at room temperature overnight, and then mixed again before use.
  • One hundred grams (100 g) of a 10% Veegum® HV solution is prepared as follows. While heating 90 g of water to 70° C., 10 g Veegum® HV is added with strong mixing (i.e., a vortex should turn). Mixing is continued for 30 minutes at 70° C. The mixture is removed from the heat and mixing is continued for another hour. The mixture is left at room temperature overnight, and then mixed again before use.
  • Example 3 The formulation of Example 3 is prepared as follows. In Tank 1 , the menthol, eucalyptol, and dimethylacetamide (DMA) are mixed together until the solution is completely dissolved and clear. Syloid 244 FP is then added to form a homogenous gel. In Tank 2 is placed the olive oil, lemon oil, Vitamin E TPGS, propylparaben, glyceryl monostearate, and DC Elastomer 10, and heated to 70° C. (degrees Celsius) while mixing. In Tank 3 (the main tank) is added the designated amount of 10% Veegum® HV solution and water together, and mixed for 15 minutes.
  • DMA dimethylacetamide
  • the ibuprofen, potassium hydroxide (KOH), methylparaben, and L-Arginine base are then added, heated to 70° C. (degrees Celsius) and mixed for about 15 minutes until no solid exists.
  • 70° C. (degrees Celsius) the oil phase from tank 2 is added to tank 3 and mixed for 5 minutes before starting to cool the tank. While cooling, 2.5% Carbopol® 980NF solution is added.
  • phenoxyethanol and the homogeneous gel from tank 1 are added to tank 3 , and mixed for another 30 minutes.
  • the ibuprofen active ingredient in the Batch 176ZX03 formulation was stable at 22 degrees Celsius (22° C.) for more than 7 months with no degradation in the ibuprofen concentration and also no deterioration in the integrity of the formulation or emulsion.
  • Example 4 The formulation of Example 4 is prepared as follows. In Tank 1 , mix menthol, eucalyptus oil, 1-methyl-2-pyrrolidinone, phenoxyethanol, and ibuprofen together until the solution is completely dissolved and clear. In Tank 2 put the olive oil, lemon oil, Vitamin E TPGS, propylparaben, glyceryl stearate, DC Elastomer 10 and stearyl alcohol together and heat to 70° C. (degrees Celsius) while mixing. In Tank 3 (Main tank), add the methylparaben, L-arginine base, and citric acid into water. Add xanthan gum in with strong mixing, heat to 70° C. (degrees Celsius) and mix for 15 minutes until no solid exists. At 70° C. (degrees Celsius), add oil phase from tank 2 into tank 3 . Mix for 5 minutes, and start to cool the tank. At 40° C. (degrees Celsius), add solution in tank 1 , and mix for another 30 minutes.
  • the formulation BC1-170C was found to be stable at 40° C. (degrees Celsius) for 13 months.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
US12/557,470 2008-09-10 2009-09-10 Ibuprofen for Topical Administration Abandoned US20100137443A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/557,470 US20100137443A1 (en) 2008-09-10 2009-09-10 Ibuprofen for Topical Administration
US13/604,040 US9561174B2 (en) 2008-09-10 2012-09-05 Ibuprofen for topical administration
US15/383,381 US20170095433A1 (en) 2008-09-10 2016-12-19 Ibuprofen for Topical Administration
US16/576,336 US20200009095A1 (en) 2008-09-10 2019-09-19 Ibuprofen for Topical Administration

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9567208P 2008-09-10 2008-09-10
US12/557,470 US20100137443A1 (en) 2008-09-10 2009-09-10 Ibuprofen for Topical Administration

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/604,040 Continuation US9561174B2 (en) 2008-09-10 2012-09-05 Ibuprofen for topical administration

Publications (1)

Publication Number Publication Date
US20100137443A1 true US20100137443A1 (en) 2010-06-03

Family

ID=41447140

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/557,470 Abandoned US20100137443A1 (en) 2008-09-10 2009-09-10 Ibuprofen for Topical Administration
US13/604,040 Active US9561174B2 (en) 2008-09-10 2012-09-05 Ibuprofen for topical administration
US15/383,381 Abandoned US20170095433A1 (en) 2008-09-10 2016-12-19 Ibuprofen for Topical Administration
US16/576,336 Abandoned US20200009095A1 (en) 2008-09-10 2019-09-19 Ibuprofen for Topical Administration

Family Applications After (3)

Application Number Title Priority Date Filing Date
US13/604,040 Active US9561174B2 (en) 2008-09-10 2012-09-05 Ibuprofen for topical administration
US15/383,381 Abandoned US20170095433A1 (en) 2008-09-10 2016-12-19 Ibuprofen for Topical Administration
US16/576,336 Abandoned US20200009095A1 (en) 2008-09-10 2019-09-19 Ibuprofen for Topical Administration

Country Status (6)

Country Link
US (4) US20100137443A1 (pt)
EP (2) EP2373346B1 (pt)
AU (1) AU2009291755B2 (pt)
BR (1) BRPI0918142A2 (pt)
CA (2) CA2749941C (pt)
WO (1) WO2010030821A2 (pt)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120259018A1 (en) * 2009-12-16 2012-10-11 Bergman Jeffrey Stuart Composition of dexibuprofen transdermal hydrogel
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US10881616B2 (en) * 2016-01-20 2021-01-05 Cubic Pharmaceuticals Ltd. Process of preparing active pharmaceutical ingredient salts
US11007161B1 (en) * 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0918142A2 (pt) 2008-09-10 2015-12-01 Biochemics Inc composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico
MX349176B (es) 2008-09-22 2017-07-14 Biochemics Inc Suministro transdermico de farmaco empleando un osmolito y un agente vasoactivo.
CN102854263B (zh) * 2012-08-31 2014-04-16 石家庄中硕药业集团有限公司 一种同时测定布洛芬注射液中布洛芬及精氨酸含量的方法
WO2016137411A1 (en) 2015-02-25 2016-09-01 Pharmactive İlaç Sanayi Ve Ticaret A. Ş. Topical spray composition comprising ibuprofen and lidocaine
EP3624770A1 (en) 2017-05-15 2020-03-25 BioChemics, Inc. Transdermally-delivered combination drug therapy for pain
CN111683671A (zh) 2017-10-06 2020-09-18 嘉吉公司 制备马黛茶提取物组合物的方法
CA3112808A1 (en) 2018-09-27 2020-04-02 BioPhysics Pharma, Inc. Transdermal drug delivery system
BR112021019944A2 (pt) 2019-04-06 2021-12-07 Cargill Inc Métodos para fabricação de uma composição cafeoilquínica, para isolar uma composição cafeoilquínica de biomassa de erva e para isolar uma composição de glicosídeo de esteviol e uma composição cafeoilquínica da biomassa de estévia, composição, composição ingerível, e, bebida ou produto alimentício

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388125A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Medicament

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4185100A (en) * 1976-05-13 1980-01-22 Johnson & Johnson Topical anti-inflammatory drug therapy
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4440777A (en) 1981-07-07 1984-04-03 Merck & Co., Inc. Use of eucalyptol for enhancing skin permeation of bio-affecting agents
US4933184A (en) 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4663364A (en) 1984-09-05 1987-05-05 Kao Corporation Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder
US4859704A (en) 1987-10-15 1989-08-22 Oratech Pharmaceutical Development Corporation Water soluble ibuprofen compositions and methods of making them
AU6974191A (en) 1989-12-20 1991-07-18 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
US5093133A (en) * 1990-01-24 1992-03-03 Mcneil-Ppc, Inc. Method for percutaneous delivery of ibuprofen using hydroalcoholic gel
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5210099A (en) 1991-02-11 1993-05-11 American Home Products Corporation Analgesic compositions
ES2148175T3 (es) 1991-05-13 2000-10-16 Boots Co Plc Composicion farmaceutica que contiene una sal de ibuprofeno.
US5229130A (en) 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US5853751A (en) 1993-06-23 1998-12-29 Masiz; John J. Molecular transdermal transport system
US5645854A (en) 1993-06-23 1997-07-08 Masiz; John J. Molecular transdermal transport system
US5460821A (en) 1993-06-23 1995-10-24 Masiz; John J. Molecular transdermal transport system
IT1265001B1 (it) 1993-12-16 1996-10-17 Zambon Spa Composizione farmaceutica per uso topico contenente acido (s)-2-(4- isobutilfenil) propionico
DE19509807A1 (de) 1995-03-21 1996-09-26 Basf Ag Verfahren zur Herstellung von Wirkstoffzubereitungen in Form einer festen Lösung des Wirkstoffs in einer Polymermatrix sowie mit diesem Verfahren hergestellte Wirkstoffzubereitungen
US5654337A (en) 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
FR2732221B1 (fr) 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
FR2741262B1 (fr) 1995-11-20 1999-03-05 Oreal Utilisation d'un antagoniste de tnf-alpha pour le traitement des rougeurs cutanees d'origine neurogene
US5976566A (en) 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6207713B1 (en) 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US5895658A (en) 1997-09-17 1999-04-20 Fossel; Eric T. Topical delivery of L-arginine to cause tissue warming
US5922332A (en) 1997-09-17 1999-07-13 Fossel; Eric T. Topical delivery of arginine to overcome pain
US6306130B1 (en) 1998-04-07 2001-10-23 The General Hospital Corporation Apparatus and methods for removing blood vessels
US6368618B1 (en) 1999-07-01 2002-04-09 The University Of Georgia Research Foundation, Inc. Composition and method for enhanced transdermal absorption of nonsteroidal anti-inflammatory drugs
US7105172B1 (en) 1999-11-18 2006-09-12 Bolla John D Treatment of rosacea
US6645520B2 (en) * 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
DE10001546A1 (de) 2000-01-14 2001-07-19 Beiersdorf Ag Verfahren zur kontinuierlichen Herstellung und Beschichtung von Selbstlebemassen auf Basis von Polyisobutylen mit mindestens einem pharmazeutischen Wirkstoff
FR2808191B1 (fr) 2000-04-28 2004-03-05 Oreal Extrait de vegetal de l'espece olea europaea comme inhibiteur de no-synthase et utilisations
US6635274B1 (en) 2000-10-27 2003-10-21 Biochemics, Inc. Solution-based transdermal drug delivery system
CA2486553C (en) * 2002-06-17 2012-01-10 Taro Pharmaceuticals U.S.A., Inc. Ibuprofen suspension
US20070292461A1 (en) * 2003-08-04 2007-12-20 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US6927206B2 (en) 2003-06-06 2005-08-09 Procyte Corporation Compositions and methods for treatment of rosacea
EP1588697A1 (en) * 2004-04-16 2005-10-26 Kurt H. Prof. Dr. Bauer Emulsion gel for topical application of pharmaceuticals
WO2005102307A2 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20050256204A1 (en) 2004-05-11 2005-11-17 Bitter Patrick H Sr Topical phenyl-epinephrine Rosacea treatment
US7433356B2 (en) * 2004-05-13 2008-10-07 International Business Machines Corporation Methods and apparatus for creating addresses
US20060013866A1 (en) * 2004-07-16 2006-01-19 Carter Stephen G Transdermal drug delivery formulations with optimal amounts of vasodilators therein
US7288263B2 (en) 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
DE102005000755A1 (de) * 2005-01-04 2006-07-20 Continental Aktiengesellschaft Fahrzeugluftreifen
US20060217690A1 (en) 2005-03-22 2006-09-28 Bastin Norman J Method for treating various dermatological and muscular conditions using electromagnetic radiation
CA2645073A1 (en) 2006-03-08 2007-09-13 Nuviance, Inc. Transdermal drug delivery compositions and topical compositions for application on the skin
JP5406531B2 (ja) * 2006-10-12 2014-02-05 ロート製薬株式会社 皮膚外用剤
US8354116B2 (en) 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
BRPI0918142A2 (pt) 2008-09-10 2015-12-01 Biochemics Inc composição farmaclógica tópica, seu método de preparação, bem como uso da forma de ácido livre de ácido 2-(4-isobutifilfenil)prpiônico

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0388125A1 (en) * 1989-03-14 1990-09-19 Beecham Group Plc Medicament

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Akhter et al. "Absorption through human skin of ibuprofen and flurbiprofen; effect of dose variation, deposited drug films, occlusion and the penetration enhancer N-methyl-2-pyrrolidone". J. Pharm. Pharmacol. 1985, 37: 27-37. *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120259018A1 (en) * 2009-12-16 2012-10-11 Bergman Jeffrey Stuart Composition of dexibuprofen transdermal hydrogel
US20150342879A1 (en) * 2009-12-16 2015-12-03 Shasun Pharmaceuticals Limited Composition of dexibuprofen transdermal hydrogel
US10085939B2 (en) * 2009-12-16 2018-10-02 Strides Shasun Limited Composition of dexibuprofen transdermal hydrogel
US10561627B2 (en) 2014-12-31 2020-02-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermetic surfactant films
US10596117B1 (en) 2014-12-31 2020-03-24 Eric Morrison Lipoleosomes as carriers for aromatic amide anesthetic compounds
US11007161B1 (en) * 2014-12-31 2021-05-18 Eric Morrison Ibuprofen nanoparticle carriers encapsulated with hermatic surfactant films
US10881616B2 (en) * 2016-01-20 2021-01-05 Cubic Pharmaceuticals Ltd. Process of preparing active pharmaceutical ingredient salts
US11504327B1 (en) 2019-01-21 2022-11-22 Eric Morrison Method of preparing nanoparticles by hot-melt extrusion

Also Published As

Publication number Publication date
WO2010030821A3 (en) 2011-01-20
AU2009291755B2 (en) 2016-04-21
US20200009095A1 (en) 2020-01-09
BRPI0918142A2 (pt) 2015-12-01
CA2726726A1 (en) 2010-03-18
US20120329875A1 (en) 2012-12-27
US20170095433A1 (en) 2017-04-06
US9561174B2 (en) 2017-02-07
AU2009291755A1 (en) 2010-03-18
CA2749941C (en) 2018-04-24
CA2749941A1 (en) 2010-03-18
EP2373346A2 (en) 2011-10-12
EP2373346B1 (en) 2019-06-12
EP3574921A1 (en) 2019-12-04
WO2010030821A2 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
US20200009095A1 (en) Ibuprofen for Topical Administration
JP6802879B2 (ja) 勃起不全および他の適応症の処置
US7052715B2 (en) Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
US10821075B1 (en) Compositions for topical application of a medicaments onto a mammalian body surface
Mandal et al. Future aspects and applications of nanoemulgel formulation for topical lipophilic drug delivery
US7781429B2 (en) Vehicle for topical delivery of anti-inflammatory compounds
US20060241175A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
Alsaab et al. Organogels in drug delivery: A special emphasis on pluronic lecithin organogels
KR20120106933A (ko) 이부프로펜을 함유하는 국소 조성물
US9289495B2 (en) Systems and methods for treatment of allergies and other indications
US20170281580A1 (en) Topical diclofenac sodium compositions
EP1858556A1 (en) Vehicle for topical delivery of anti-inflammatory compounds
EP3853204A1 (en) Improved and stable apremilast pharmaceutical compositions
JP2012092067A (ja) 非ステロイド性消炎鎮痛外用剤
EP4041211A1 (en) Improved topical composition of colchicine
US20060263439A1 (en) Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof
US20220040138A1 (en) Teriflunomide topical pharmaceutical compositions
WO2021232123A1 (pt) Plataforma para mascaramento de sabor
TR2023019879A2 (tr) Kolşi̇si̇n i̇le febuksostat nanokri̇stalleri̇ni̇ bi̇r arada i̇çeren oral i̇nce fi̇lm formülasyonlari

Legal Events

Date Code Title Description
AS Assignment

Owner name: BIOCHEMICS, INC.,MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CARTER, STEPHEN G.;ZHU, ZHEN;PATEL, KANU;AND OTHERS;SIGNING DATES FROM 20090925 TO 20090930;REEL/FRAME:023907/0216

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: BIO STRATEGIES, LP, TEXAS

Free format text: SECURITY INTEREST;ASSIGNOR:BIOCHEMICS, INC.;REEL/FRAME:033086/0888

Effective date: 20131213